US › Healthcare

OnKure Therapeutics, Inc. (OKUR)

US · Healthcare · Biotechnology

$4.10+1.99%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-15.2M
Profit YoY
+4.8%
EPS
$-1.11
EPS estimate
$-0.74

EPS came in at -1.11 against a street estimate of -0.74 — a miss of 50.0%.

Key statistics

Market cap
$154.3M
Forward P/E
0.0
P/B
0.84
Book value
$4.56
EPS (TTM)
$-4.32
52-week high
$5.38
52-week low
$1.91
50-day MA
$4.23
200-day MA
$3.56

Analyst view

Analysts rate OnKure Therapeutics, Inc. a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $19.50.

Shareholding

Insiders
10.47%
Institutions
76.80%

Largest institutional holders

FundStake
RA Capital Management, LLC9.90%
StepStone Group LLC6.59%
ADAR1 Capital Management LLC6.03%
Prosight Management, LP5.33%
Bvf Inc4.90%
Vivo Capital, LLC4.77%
Vestal Point Capital LP4.55%
Foresite Capital Management VI LLC3.58%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for OnKure Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.